Nimodipine

Nimodipine, also known under the brand name nimotop, is a calcium channel blocker typically used for ischemic stroke, migraine prevention and subarachnoid hemorhage.

Evidence
Evidence for the use of nimodipine in patients with ME/CFS is extremely limited, mostly based on personal experiences rather than clinical trials, and with mixed results reported in patients.

In 1996, Dr Ellen Wiebe published case studies of two patients with ME/CFS, including a moderately ill patient who noticed improvements in fatigue, cognitive function and muscle pain after starting nimodipine. In 1998, three British doctors with a special interest in ME/CFS, stated that in their experience nimodipine and other calcium channel blockers were ineffective in patients chronic fatigue syndrome.

Notable studies

 * 1996, N of 1 trials: Managing patients with chronic fatigue syndrome: two case reports

Articles and blogs

 * 2016, NIMODIPINE use in ME/CFS: An introduction - Susan Parker
 * 2014 Chronic Fatigue Syndrome - Proc. R. Coll. Physicians Edinb. 1998; 28:150-163 - A. Chaudhuri, Wilhelmina M.H. Behan and P.O. Behan, Southern General Hospital, Glasgow and Western Infirmary, Glasgow
 * 2014, NIMODIPINE use in ME/CFS: A comprehensive guide - Susan Parker
 * Jan 28, 2008, Brief notes on Nimodipine and ME/CFS - M.E. Association

Learn more

 * Nimodipine - drugbank.ca
 * Nimodipine - drugs.com